ES2183351T3 - Composicones que comprenden conjugados de proteina ob humana activa estable con una cadena fc de inmunoglobulinas y metodos. - Google Patents
Composicones que comprenden conjugados de proteina ob humana activa estable con una cadena fc de inmunoglobulinas y metodos.Info
- Publication number
- ES2183351T3 ES2183351T3 ES98918399T ES98918399T ES2183351T3 ES 2183351 T3 ES2183351 T3 ES 2183351T3 ES 98918399 T ES98918399 T ES 98918399T ES 98918399 T ES98918399 T ES 98918399T ES 2183351 T3 ES2183351 T3 ES 2183351T3
- Authority
- ES
- Spain
- Prior art keywords
- compositions
- immunoglobulins
- chain
- methods
- human protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 title 1
- 102000018358 immunoglobulin Human genes 0.000 title 1
- 229940072221 immunoglobulins Drugs 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000016267 Leptin Human genes 0.000 abstract 3
- 108010092277 Leptin Proteins 0.000 abstract 3
- 239000000725 suspension Substances 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Obesity (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84397197A | 1997-04-17 | 1997-04-17 | |
| US09/059,467 US20020019352A1 (en) | 1997-04-17 | 1998-04-14 | Stable, active, human ob protein compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2183351T3 true ES2183351T3 (es) | 2003-03-16 |
Family
ID=26738785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES98918399T Expired - Lifetime ES2183351T3 (es) | 1997-04-17 | 1998-04-16 | Composicones que comprenden conjugados de proteina ob humana activa estable con una cadena fc de inmunoglobulinas y metodos. |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0977583B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP4086908B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN1202862C (cg-RX-API-DMAC10.html) |
| AT (1) | ATE223229T1 (cg-RX-API-DMAC10.html) |
| AU (1) | AU7132798A (cg-RX-API-DMAC10.html) |
| CA (1) | CA2286098C (cg-RX-API-DMAC10.html) |
| DE (1) | DE69807679T2 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2183351T3 (cg-RX-API-DMAC10.html) |
| HU (1) | HU226175B1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL132380A0 (cg-RX-API-DMAC10.html) |
| WO (1) | WO1998046257A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6936439B2 (en) | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
| US20030040467A1 (en) | 1998-06-15 | 2003-02-27 | Mary Ann Pelleymounter | Ig/ob fusions and uses thereof. |
| CA2236163A1 (en) * | 1995-11-22 | 1997-05-29 | Amgen Inc. | Methods of increasing lean tissue mass using ob protein compositions |
| ES2221717T3 (es) | 1997-12-08 | 2005-01-01 | Emd Lexigen Research Center Corp. | Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general. |
| US7488590B2 (en) | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
| ATE348163T1 (de) | 1998-10-23 | 2007-01-15 | Amgen Inc | Thrombopoietin substitute |
| US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| AU1134000A (en) * | 1998-10-27 | 2000-05-15 | Eli Lilly And Company | Prevention of muscle mass loss with leptin receptor ligands |
| US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| WO2001010912A1 (en) | 1999-08-09 | 2001-02-15 | Lexigen Pharmaceuticals Corp. | Multiple cytokine-antibody complexes |
| CA2391080A1 (en) | 1999-11-12 | 2001-05-25 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Erythropoietin forms with improved properties |
| JP5179689B2 (ja) | 2000-02-11 | 2013-04-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗体ベース融合タンパク質の循環系内半減期の増強 |
| US20020090646A1 (en) * | 2000-05-03 | 2002-07-11 | Amgen Inc. | Calcitonin-related molecules |
| EP1278778A2 (en) * | 2000-05-03 | 2003-01-29 | Amgen Inc., | Modified peptides, comprising an fc domain, as therapeutic agents |
| CZ2003214A3 (cs) | 2000-06-29 | 2003-08-13 | Merck Patent Gmbh | Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu |
| WO2002057435A2 (en) * | 2001-01-18 | 2002-07-25 | Merck Patent Gmbh | Bifunctional fusion proteins with glucocerebrosidase activity |
| DK1366067T3 (da) | 2001-03-07 | 2012-10-22 | Merck Patent Gmbh | Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed |
| US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| BR0209177A (pt) | 2001-05-03 | 2004-10-05 | Merck Patent Gmbh | Anticorpo especìfico a tumor recombinante e uso do mesmo |
| EP1454138B1 (en) | 2001-12-04 | 2012-01-18 | Merck Patent GmbH | Immunocytokines with modulated selectivity |
| MXPA04011470A (es) | 2002-05-21 | 2005-02-14 | Amgen Inc | Compuestos heterociclicos sustituidos y metodos de uso. |
| ATE471946T1 (de) | 2002-12-17 | 2010-07-15 | Merck Patent Gmbh | Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2 |
| KR101163424B1 (ko) | 2003-12-30 | 2012-07-13 | 메르크 파텐트 게엠베하 | Il-7 융합 단백질 |
| EP1699821B1 (en) | 2003-12-31 | 2012-06-20 | Merck Patent GmbH | Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS |
| CA2552590A1 (en) | 2004-01-05 | 2005-07-21 | Emd Lexigen Research Center Corp. | Interleukin-12 targeted to oncofoetal fibronectin |
| CA2580796C (en) | 2004-09-24 | 2013-03-26 | Amgen Inc. | Modified fc molecules having peptides inserted in internal loop regions |
| CN101072793B (zh) | 2004-12-09 | 2012-06-20 | 默克专利有限公司 | 具有降低的免疫原性的il-7变体 |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| US8227408B2 (en) | 2005-09-07 | 2012-07-24 | Neurotez, Inc. | Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology |
| TW201920257A (zh) | 2008-04-11 | 2019-06-01 | 日商中外製藥股份有限公司 | 重複結合複數個抗原的抗原結合分子 |
| KR20110028457A (ko) | 2008-05-21 | 2011-03-18 | 뉴로테즈 인코포레이티드 | 신경섬유 매듭과 연관된 신경변성 장애를 치료하는 방법 |
| WO2009149379A2 (en) | 2008-06-05 | 2009-12-10 | Regents Of The University Of Michigan | Use of leptin for the treatment of fatty liver diseases and conditions |
| CA2742600A1 (en) | 2008-11-04 | 2010-05-14 | Nikolaos Tezapsidis | Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta |
| AU2010238858A1 (en) | 2009-04-22 | 2011-12-08 | Merck Patent Gmbh | Antibody fusion proteins with modified FcRn binding sites |
| TWI654203B (zh) | 2010-11-30 | 2019-03-21 | Chugai Seiyaku Kabushiki Kaisha | 具有鈣依存性的抗原結合能力之抗體 |
| SG10201609665PA (en) | 2011-02-25 | 2017-01-27 | Chugai Pharmaceutical Co Ltd | FcɣRIIb-SPECIFIC Fc ANTIBODY |
| JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| CN111529535A (zh) | 2012-09-27 | 2020-08-14 | 儿童医学中心公司 | 用于治疗肥胖症的化合物和其使用方法 |
| PT3074033T (pt) | 2013-11-26 | 2019-02-08 | Childrens Medical Ct Corp | Compostos para o tratamento de obesidade e métodos de utilização dos mesmos |
| US20170209408A1 (en) | 2014-04-03 | 2017-07-27 | The Children's Medical Center Corporation | Hsp90 inhibitors for the treatment of obesity and methods of use thereof |
| MX2017005774A (es) | 2014-12-19 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. |
| EA201791366A1 (ru) | 2014-12-19 | 2018-02-28 | Чугаи Сейяку Кабусики Кайся | Антитела к c5 и способы их применения |
| CN114773469B (zh) | 2015-02-05 | 2025-12-19 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il-8-结合抗体及其应用 |
| EP3394098A4 (en) | 2015-12-25 | 2019-11-13 | Chugai Seiyaku Kabushiki Kaisha | ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE |
| CN116271014A (zh) | 2016-08-05 | 2023-06-23 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
| DK3509624T3 (da) | 2016-09-12 | 2023-11-13 | Amryt Pharmaceuticals Inc | Fremgangsmåder til detektering af anti-leptin-neutraliserende antistoffer |
| WO2018139623A1 (en) | 2017-01-30 | 2018-08-02 | Chugai Seiyaku Kabushiki Kaisha | Anti-sclerostin antibodies and methods of use |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5559208A (en) * | 1995-01-31 | 1996-09-24 | Eli Lilly And Company | Anti-obesity proteins |
| GB9511935D0 (en) * | 1995-06-13 | 1995-08-09 | Smithkline Beecham Plc | Novel compound |
| IL124831A0 (en) * | 1995-12-27 | 1999-01-26 | Genentech Inc | Ob protein derivatives having prolonged half-life |
| EP1835030A1 (en) * | 1996-12-20 | 2007-09-19 | Amgen, Inc. | OB fusion protein compositions and methods |
-
1998
- 1998-04-16 IL IL13238098A patent/IL132380A0/xx active IP Right Grant
- 1998-04-16 DE DE69807679T patent/DE69807679T2/de not_active Expired - Lifetime
- 1998-04-16 JP JP54433898A patent/JP4086908B2/ja not_active Expired - Lifetime
- 1998-04-16 ES ES98918399T patent/ES2183351T3/es not_active Expired - Lifetime
- 1998-04-16 CN CNB988042258A patent/CN1202862C/zh not_active Expired - Fee Related
- 1998-04-16 HU HU0002831A patent/HU226175B1/hu not_active IP Right Cessation
- 1998-04-16 WO PCT/US1998/007828 patent/WO1998046257A1/en not_active Ceased
- 1998-04-16 AU AU71327/98A patent/AU7132798A/en not_active Abandoned
- 1998-04-16 EP EP98918399A patent/EP0977583B1/en not_active Expired - Lifetime
- 1998-04-16 AT AT98918399T patent/ATE223229T1/de active
- 1998-04-16 CA CA002286098A patent/CA2286098C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998046257A8 (en) | 2000-01-27 |
| DE69807679D1 (de) | 2002-10-10 |
| HUP0002831A2 (hu) | 2000-12-28 |
| EP0977583A1 (en) | 2000-02-09 |
| JP2002512612A (ja) | 2002-04-23 |
| WO1998046257A1 (en) | 1998-10-22 |
| HUP0002831A3 (en) | 2005-11-28 |
| AU7132798A (en) | 1998-11-11 |
| CA2286098A1 (en) | 1998-10-22 |
| EP0977583B1 (en) | 2002-09-04 |
| ATE223229T1 (de) | 2002-09-15 |
| CN1274289A (zh) | 2000-11-22 |
| JP4086908B2 (ja) | 2008-05-14 |
| HK1023513A1 (en) | 2000-09-15 |
| HU226175B1 (en) | 2008-06-30 |
| CA2286098C (en) | 2009-07-07 |
| DE69807679T2 (de) | 2003-07-31 |
| CN1202862C (zh) | 2005-05-25 |
| IL132380A0 (en) | 2001-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1329458T5 (da) | Peptider som sænker blodglucoseniveauer | |
| CO4830493A1 (es) | Anticuerpos contra cd40 humano | |
| WO1998046257A8 (en) | Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods | |
| CY1106860T1 (el) | Δομες χρωστικων ευαισθητες σε οξεα και διασπωμενες ενζυμικα για τη διαγνωστικη με ακτινοβολια εγγυς υπερυθρου και για τη θεραπεια | |
| DE69435105D1 (de) | Derivate therapeutischer Peptide | |
| BR9911444A (pt) | Agentes de tingimento para o tingimento de fibras de queratina | |
| DK1212422T3 (da) | Humane CTLA-4-antistoffer og anvendelserne deraf | |
| ES2074042T3 (es) | Exotoxina recombinante de pseudomonas construccion de una inmunotoxina activa con efectos secundarios menores. | |
| EA200100053A1 (ru) | Кальций (3s)тетрагидро-3-фуранил(1s,2r)-3-[[(4-аминофенил)сульфонил](изобутил)амино]-1-бензил-2-(фосфоноокси)пропилкарбамат | |
| CY1107708T1 (el) | Ανθρωπινα μονοκλωνικα αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης | |
| ATE415979T1 (de) | Behandlung mit anti-erbb2 antikörpern | |
| TR199903331T2 (xx) | Farnesil protein transferas engelleyicileri. | |
| CY1109421T1 (el) | ΔΟΣΕΙΣ ΓΙΑ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2 | |
| SV1995000007A (es) | Derivados del acido micofenolico 5-substituidos. | |
| EA200100939A1 (ru) | Продолжительно действующие инсулинотропные пептиды | |
| IS2819B (is) | Viðloðunarsameindir í æðum og mótun á starfsemi@þeirra | |
| DE59610251D1 (de) | Konjugat, umfassend einen wirkstoff, ein polypeptid und einen polyether | |
| ES2147519A1 (es) | Utilizacion de un compuesto de tipo retinoide para modular in vivo la actividad desacopladora de la proteina ucp2. | |
| TR199902605T2 (xx) | Fibrinojenin azalt�lma y�ntemleri. |